Market Overview:
Mesenchymal stem cells are multilineage progenitor cells that can differentiate into tissues like bone, cartilage, tendon, muscle, and fat. They are isolated from adult tissues like bone marrow, adipose tissue, dental pulp, and other tissues. Mesenchymal stem cells have significant potential in the treatment of various diseases due to their unique immunomodulatory and multilineage differentiation properties. They can be administered to patients without the risk of rejection and help regenerate damaged tissues. Mesenchymal stem cell therapy is gaining acceptance for treating diseases like graft-versus-host disease, Crohn’s disease, diabetes, multiple sclerosis, stroke, myocardial infarction, and osteoarthritis.
The mesenchymal stem cells market is estimated to be valued at US$3.05 Bn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing research activities to demonstrate the clinical efficacy of mesenchymal stem cells in various disease conditions is a major trend in the market. Several phase II and phase III clinical trials are underway to evaluate the safety and therapeutic potential of mesenchymal stem cells in diseases like graft-versus-host disease, diabetes, and osteoarthritis. Approvals of new mesenchymal stem cell products are also expected to boost the market growth over the forecast period. Moreover, development of technologies to optimize the mesenchymal stem cell isolation, expansion, and cryopreservation processes is supporting their clinical translation. Growing stem cell banking facilities worldwide for storing mesenchymal stem cells derived from different tissues is another key trend in the market.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is low as this is a specialized market that requires high investments in R&D.
Bargaining power of buyers: The bargaining power of buyers is moderate as the benefits of MSCs are still being established. This allows buyers to negotiation on price.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are several players operating in this market.
Threat of new substitutes: The threat of new substitutes is low as MSCs have unique properties that are hard to substitute.
Competitive rivalry: High as players are trying to establish themselves as leaders in this emerging market.
Key Takeaways
The Global Mesenchymal Stem Cells Market Size is expected to witness high growth, exhibiting 12% CAGR over the forecast period, due to increasing application in cell therapy and research.
The North America region currently dominates the market due to higher adoption and growing infrastructure for clinical research. However, Asia Pacific is expected to grow at the fastest rate due to rising healthcare spending and expanding stem cell research in countries like China and India.
Key players operating in the Mesenchymal Stem Cells market are Lonza Group Ltd., Thermo Fisher Scientific Inc., Merck KGaA, and STEMCELL Technologies Inc. Lonza Group Ltd. specializes in manufacturing MSCs for clinical applications. Thermo Fisher Scientific Inc. offers cultured and cryopreserved MSCs for research use.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
